Autopsy report · NCT00439192

ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)

“side effect profile did not match expectations”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 6 months before it stopped.
• 275 participants planned (an estimate, not an actual count).
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

elbion AG

Sponsor type

Industry

Conditions

Overactive Bladder; Urinary Incontinence

Interventions

ELB245; Tolterodine

Participants

275 (planned, not actual)

Sites

31

Countries

Germany, Poland, Sweden

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.